Open Access

Protective effect of gonadotropin‑releasing hormone agonist against chemotherapy‑induced ovarian dysfunction: A meta‑analysis

  • Authors:
    • Fei Zheng
    • Bin Zhu
    • Qingjing Feng
    • Lili Wu
    • Yuechong Cui
    • Yumo Liu
    • Yingqian Wang
  • View Affiliations

  • Published online on: April 15, 2019     https://doi.org/10.3892/ol.2019.10252
  • Pages: 5319-5326
  • Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The protective effects of gonadotropin‑releasing hormone agonist (GnRHa) against ovarian chemotherapy induced‑toxicity have not completely been demonstrated and the impact of chemotherapy on ovarian dysfunction remains unclear. The present meta‑analysis aimed to evaluate the efficiency of GnRHa and to determine whether GnRHa could influence the long‑term survival rate of patients with cancer. A total of 12 clinical randomized controlled trials were included, consisting of 1,413 patients who were divided into the GnRHa group (n=705) and the control group (n=708). The meta‑analysis revealed that GnRHa may significantly improve the menstrual function recovery rate in patients who received chemotherapy [RR=1.29, 95% confidence interval (CI)=1.09‑1.54, P=0.004] and reduce the rate of premature ovarian failure (RR=0.47, 95% CI=0.31‑0.71, P=0.0004). However, it had no effect on the pregnancy rate (RR=1.40, 95% CI=0.98‑1.98, P=0.06), on the rate of disease‑free survival and overall survival of patients (disease‑free survival rate: RR=1.04, 95% CI=0.95‑1.13, P=0.40; overall survival rate: RR=1.02, 95% CI=0.90‑1.16, P=0.72). In conclusion, GnRHa may reduce chemotherapy‑induced ovarian dysfunction without compromising or influencing the therapeutic effects of chemotherapy.

References

1 

Ataya KM, McKanna JA, Weintraub AM, Clark MR and LeMaire WJ: A luteinizing hormone-relasing hormone agnist for the prevention of chemotherapy-induced ovarian fllicular loss in rats. Cancer Res. 45:3651–3656. 1985.PubMed/NCBI

2 

Blumenfeld Z and Eckman A: Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Nail Cancer Inst Monogr. 34:40–43. 2005. View Article : Google Scholar

3 

Badawy A, Elnashar A, El-Ashry M and Shahat M: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril. 91:694–697. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, et al: No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: Final long-term report of a prospective randomized trial. J Clin Oncol. 34:2568–2574. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons. (Ltd., Chichester). 2008. View Article : Google Scholar

6 

Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN and Abou-Setta AM: Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: A randomized controlled trial. Obstet Gynecol. 121:78–86. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 29:2334–2341. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L and Vincenzo L: Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 12:141–147. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S and Dehghani-Tafti A: Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol. 35:59–61. 2014.PubMed/NCBI

10 

Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, et al: Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA. 314:2632–2640. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA and Coleman RE; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists, : GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Ann Oncol. 28:1811–1816. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, et al: Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 372:923–932. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB and Minton SE: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 30:533–538. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Song G, Gao H and Yuan Z: Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: Results from a phase II randomized trial. Med Oncol. 30:6672013. View Article : Google Scholar : PubMed/NCBI

15 

Sverrisdottir A, Nystedt M, Johansson H and Fornander T: Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: Results from a randomized trial. Breast Cancer Res Treat. 117:561–567. 2009. View Article : Google Scholar : PubMed/NCBI

16 

LHRH-agonists in Early Breast Cancer Overview Group, ; Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M and Sainsbury R: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 369:1711–1723. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Zheng W, Magid MS, Kramer EE and Chen YT: Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol. 148:47–53. 1996.PubMed/NCBI

18 

Periti P, Mazzei T and Mini E: Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 41:485–504. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO and Neely EK: Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 91:1862–1867. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, Baba T, Hayashi T, Chiba H, Sawada N and Saito T: Hyperstimulation and a gonadotropin releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 147:694–699. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Reinsch RC, Murphy AA, Morales AJ and Yen SS: The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: A prospective, randomized study. Am J Obstet Gynecol. 170:1623–1627. 1994. View Article : Google Scholar : PubMed/NCBI

22 

Ng EH, Tang OS, Chan CC and Ho PC: Ovarian stromal blood flow in the prediction of ovarian response during in vitro fertilization treatment. Hum Reprod. 20:3147–3151. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Jarvela IY, Sladkevicius P, Kelly S, Ojha K, Campbell S and Nargund G: Effect of pituitary down-regulation on the ovary before in vitro fertilization as measured using threedimensional power Doppler ultrasound. Fertil Steril. 79:1129–1135. 2003. View Article : Google Scholar : PubMed/NCBI

24 

Choi JH, Gilks CB, Auersperg N and Leung PC: Immunolocalization of gonadotropin-releasing hormone(GnRH)-I, GnRH-II and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab. 91:4562–4570. 2006. View Article : Google Scholar : PubMed/NCBI

25 

Imai A, Sugiyama M, Furui T, Tamaya T and Ohno T: Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest. 63:102–106. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Morita Y and Tilly JL: Oocyte apoptosis: Like sand through an hourglass. Dev Biol. 213:1–17. 1999. View Article : Google Scholar : PubMed/NCBI

27 

Reynolds T: Cell death genes may hold clues to preserving fertility after Chemotherapy. Natl Cancer Inst. 91:664–666. 1999. View Article : Google Scholar

28 

Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, Fuks Z, Xie Z, Reed JC, Schuchman EH, et al: Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 6:1109–1114. 2000. View Article : Google Scholar : PubMed/NCBI

29 

Johnson J, Canning J, Kaneko T, Pru JK and Tilly JL: Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 428:145–150. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zheng, F., Zhu, B., Feng, Q., Wu, L., Cui, Y., Liu, Y., & Wang, Y. (2019). Protective effect of gonadotropin‑releasing hormone agonist against chemotherapy‑induced ovarian dysfunction: A meta‑analysis. Oncology Letters, 17, 5319-5326. https://doi.org/10.3892/ol.2019.10252
MLA
Zheng, F., Zhu, B., Feng, Q., Wu, L., Cui, Y., Liu, Y., Wang, Y."Protective effect of gonadotropin‑releasing hormone agonist against chemotherapy‑induced ovarian dysfunction: A meta‑analysis". Oncology Letters 17.6 (2019): 5319-5326.
Chicago
Zheng, F., Zhu, B., Feng, Q., Wu, L., Cui, Y., Liu, Y., Wang, Y."Protective effect of gonadotropin‑releasing hormone agonist against chemotherapy‑induced ovarian dysfunction: A meta‑analysis". Oncology Letters 17, no. 6 (2019): 5319-5326. https://doi.org/10.3892/ol.2019.10252